JP Morgan Chase’s Legend Biotech LEGN Stock Holding History

JP Morgan Chase’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$617K	Buy	+21,000	New	+$566K	﹤0.01%	4959
2026 Q1	–	Sell	-24,000	Closed	-$522K	–	7733
2025 Q4	$522K	Buy	+24,000	New	+$687K	﹤0.01%	4992
2024 Q1	–	Sell	-190,000	Closed	-$11.4M	–	7669
2023 Q4	$11.4M	Buy	+190,000	New	+$12M	﹤0.01%	2339
2023 Q2	–	Sell	-31,000	Closed	-$1.5M	–	7152
2023 Q1	$1.5M	Sell	31,000 -171,000	-85%	-$8.36M	﹤0.01%	3750
2022 Q4	$10.1M	Sell	202,000 -36,500	-15%	-$1.77M	﹤0.01%	2244
2022 Q3	$9.73M	Hold	238,500	–	–	﹤0.01%	2164
2022 Q2	$13.1M	Hold	238,500	–	–	﹤0.01%	1945
2022 Q1	$8.67M	Buy	+238,500	New	+$9.42M	﹤0.01%	2518
2021 Q3	–	Sell	-30,000	Closed	-$1.23M	–	6654
2021 Q2	$1.23M	Buy	+30,000	New	+$1.02M	﹤0.01%	4151

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

JP Morgan Chase's LEGN Position: Q2 2026 in Review

JP Morgan Chase increased its Legend Biotech (LEGN) stake by 166% in Q2 2026, buying an estimated $12.9M and bringing the position to 766,364 shares worth $22.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2124.

JP Morgan Chase first reported a position in LEGN in Q2 2020 and has held it in 25 quarters since. The position peaked at $39.7M in Q2 2023. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

JP Morgan Chase held 766,364 shares of Legend Biotech worth $22.5M as of Q2 2026.
JP Morgan Chase bought 478,261 Legend Biotech shares in Q2 2026, an estimated $12.9M.
Legend Biotech made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2124 holding.
JP Morgan Chase first reported a position in Legend Biotech in Q2 2020 and has held it in 25 quarters since.
JP Morgan Chase's Legend Biotech position peaked at $39.7M in Q2 2023.
219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.